Cours Biosyent Inc. Toronto S.E.
Actions
RX
CA0906901081
Produits pharmaceutiques
CA 2024 * | 35 M 25,58 M 22,62 M | CA 2025 * | 38,7 M 28,29 M 25,01 M | Capitalisation | 116 M 84,72 M 74,91 M |
---|---|---|---|---|---|
Résultat net 2024 * | - | Résultat net 2025 * | - | VE / CA 2024 * | 3,31 x |
Trésorerie nette 2024 * | - 0 0 | Trésorerie nette 2025 * | - 0 0 | VE / CA 2025 * | 3 x |
PER 2024 * |
18,2
x | PER 2025 * |
15,9
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 60,64% |
Dernier transcript sur Biosyent Inc.
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 64 | 01/01/96 |
Robert March
DFI | Director of Finance/CFO | - | 10/09/18 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/14 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 08/01/18 |
René Goehrum
CEO | Chief Executive Officer | 64 | 01/01/96 |
Peter Lockhard
BRD | Director/Board Member | 60 | 01/06/02 |
Varia. 1 janv. | Capi. | |
---|---|---|
+55,35% | 815 Md | |
+32,14% | 597 Md | |
-0,10% | 377 Md | |
+15,47% | 319 Md | |
+13,10% | 310 Md | |
+16,11% | 247 Md | |
+14,03% | 228 Md | |
+16,54% | 180 Md | |
+4,31% | 170 Md |